Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Will be Virtual Boston USA March 6-10, 2021 Back

Tweet

New PrEP at CROI 2021       Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)   CROI: NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)   CROI: ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)   CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/18/21)   CROI: LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)   CROI: PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS - (03/11/21)   CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)   CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)   CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)   CROI: Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 - (03/10/21)   CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS - (03/08/21)   CROI: Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP - (03/26/21)   CROI: WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M - (03/11/21)